Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 838

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 5
Chunk 838
---
 party transaction.

Management
will present to the audit committee each proposed related party transaction, including all relevant facts and circumstances relating
thereto. Under the policy, we may consummate related party transactions only if our audit committee approves or ratifies the transaction
in accordance with the guidelines set forth in the policy. The policy does not permit any director or executive officer to participate
in the discussion of, or decision concerning, a related person transaction in which he or she is the related party.

Director
Independence

We
will be a “controlled company” within the meaning of the Nasdaq rules prior to the consummation of our initial business combination.
As a controlled company, we will not be required to comply with the Nasdaq rules that require that a majority of our board of directors
be independent. An “independent director” is defined generally as a person who has no material relationship with the listed
company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company). Our board
of directors has determined that each of Huifeng Chang, Jim Mao and Kevin Vassily are “independent directors” as defined
in the Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only
independent directors are present.

32

Item
14. Principal Accountant Fees and Services.

The
following is a summary of fees paid or to be paid to Marcum Asia CPAs LLP, for services rendered in 2024 and Marcum LLP for services
rendered in 2023.

Audit Fees. Audit
fees consist of fees billed for professional services rendered for the audit of our financial statements, reviews of our quarterly financial
statements and services that are normally provided by our independent registered public accounting firm in connection with statutory
and regulatory filings. The aggregate fees billed by Marcum Asia CPAs LLP for audit fees, inclusive of the interim review and review
of the Registration Statement on Form S-4 and required filings with the SEC for the year ended December 31, 2024, totaled $108,544. The
aggregate fees billed by Marcum LLP for audit fees, inclusive of the interim review and review of the Registration Statement on Form
S-4 filed by Holdco in connection with the Longevity Business Combination and required filings with the SEC for the year ended December
31, 2023, totaled $236,665.

Audit-Related
Fees. Audit-related fees consist of fees billed for assurance